Page 47 - 78_04

BASES
MOLECULARES
DE
LA
ESQUIZOFRENIA

60. Zafra,
F.;
Aragón,
C.;
Olivares,
L.;
Danbolt,
N.C.;
Giménez,
C.
&
Storm-­-Mathisen,
J.
(1995)

Glycine
transporters
are
differentially
expressed
among
CNS
cells.
Journal
of

Neuroscience
15,
3952-­-3969.

61. Zafra,
F.;
Gomeza,
J.;
Olivares,
L.;
Aragón,
C.
&
Giménez,
C.
(1995)
Regional
distribution

and
developmental
variation
of
the
glycine
transporters
GLYT1
and
GLYT2
in
the
rat
CNS.

European
Journal
of
Neuroscience
7,
1342-­-1352.

62. Cubelos,
B.;
Giménez,
C.
&
Zafra,
F.
(2005)
Localization
of
the
GLYT1
glycine
transporter
at

glutamatergic
synapses
in
the
rat
brain.
Cerebral
Cortex
15,
448-­-459.

63. Cubelos,
B.;
González-­-González,
I.M.;
Giménez,
C.
&
Zafra,
F.
(2005)
The
scaffolding
protein

PSD-­-95
interacts
with
the
glycine
transporter
GLYT1
and
impairs
its
internalization.

Journal
of
Neurochemistry
95,
1047-­-1058.

64. González-­-González,
I.
M.;
García-­-Tardón,
N.;
Cubelos,
B.;
Giménez,
C.
&
Zafra,
F.
(2008)
The

glutamate
transporter
GLT1b
interacts
with
the
scaffold
protein
PSD-­-95.
Journal
of

Neurochemistry
105,
1834-­-1848.

65. Krystal,
J.H.;
Anand,
A.
&
Moghaddam,
B.
(2002)
Effects
of
NMDA
receptor

antagonists:implications
for
the
pathophysiology
of
schizophrenia.
Archives
of
General

Psychiatry
59,
663-­-664.

66. Abi-­-Saab,
W.M.;
D'Souza,
D.
C.;
Moghaddam,
B.
&
Krystal,
J.
H.
(1998)
The
NMDA

antagonist
model
for
schizophrenia:
promise
and
pitfalls.
Pharmacopsychiatry
31

Suppl2,104-­-109.

67. Krystal,
J.H.;
Karper,
L.
P.;
Seibyl,
J.
P.;
Freeman,
G.
K.;
Delaney,
R.;
Bremner,
J.
D.;
Heninger,

G.
R.;
Bowers,
M.
B.
Jr.
&
Charney,
D.
S.
(1994)
Subanesthetic
effects
of
the
noncompetitive

NMDA
antagonist,
ketamine,
in
humans.
Psychotomimetic,
perceptual,
cognitive,
and

neuroendocrine
responses.
Archives
of
General
Psychiatry
51,
199-­-214.

68. Sur,
C.
&
Kinney,
G.
G.
(2007)
Glycine
transporter
1
inhibitors
and
modulation
of
NMDA

receptor-­-mediated
excitatory
neurotransmission.
Current
Drug
Target
8,
643-­-649.

69. Lindsley,
C.
W.;
Zhao,
Z.;
Leister,
W.
H.;
O'Brien,
J.;
Lemaire,
W.;
Williams.
D.
L.
Jr.;
Chen,
T.

B.;
Chang,
R,
S.;
Burno,
M.;
Jacobson,
M.
A.;
Sur,
C.;
Kinney,
G.
G.;
Pettibone,
D.
J.;
Tiller,
P.
R.;

Smith,
S.;
Tsou,
N.
N.;
Duggan,
M.
E.,
Conn,
P.
J.
&
Hartman,
G.
D.
(2006)
Design,
synthesis,

and
in
vivo
efficacy
of
glycine
transporter-­-1
(GlyT1)
inhibitors
derived
from
a
series
of[4-­-
phenyl-­-1-­-(propylsulfonyl)piperidin-­-4-­-yl]methylbenzamides.
Chemical

Medicine

8,
807-­-
811.

70. Rogers,
B.
N.
&
Schmidt,
C.
J.
(2006)
Novel
approaches
for
the
treatment
of
schizophrenia.

Annual
Reports
in
Medicinal
Chemistry
41,
1-­-21.

71. Sur,
C.
&
Kinney,
G.
(2007)
Glycine
transporter
1
inhibitors
and
modulation
of
NMDA

receptor-­-mediated
excitatory
neurotransmission.
Current
Drug
Targets
8,
643-­-649.

72. Dohi,
T.;
Morita,
K.;
Kitiyama,
T.;
Motoyama,
N.
&
Morioka,
N.
(2009)
Glycine
transporter

inhibitors
as
a
novel
drug
discovery
strategy
for
neuropathic
pain.
Pharmacology
and

Terapeuthics
123,
54-­-79.

445